Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ziftomenib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
    Kura Oncology to partner with Kyowa Kirin for blood cancer therapy

    22 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/in/news-releases/kura-oncology-and-kyowa-kirin-announce-global-strategic-collaboration-to-develop-and-commercialize-ziftomenib-in-acute-leukemias-302312119.html

    PR NEWSWIRE
    22 Nov 2024
    Share Share
    Kura Oncology Reports Preclinical Data For Ziftomenib In GIST
    Kura Oncology Reports Preclinical Data For Ziftomenib In GIST

    24 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/10/24/2968596/35186/en/Kura-Oncology-Reports-Preclinical-Data-Supporting-Opportunity-for-Ziftomenib-in-Treatment-of-Gastrointestinal-Stromal-Tumors-GIST.html

    GLOBENEWSWIRE
    24 Oct 2024
    Share Share
    Kura Oncology Publishes Ziftomenib Ph 1 Results In The Lancet
    Kura Oncology Publishes Ziftomenib Ph 1 Results In The Lancet

    30 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/en/news-release/2024/09/30/2955703/35186/en/Kura-Oncology-Announces-Publication-of-Ziftomenib-Phase-1-Results-in-The-Lancet-Oncology.html

    GLOBENEWSWIRE
    30 Sep 2024
    Share Share
    Kura Oncology Announces FDA Clearance Of IND For Ziftomenib In GIST
    Kura Oncology Announces FDA Clearance Of IND For Ziftomenib In GIST

    08 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/08/2926821/35186/en/Kura-Oncology-Announces-FDA-Clearance-of-IND-Application-for-Menin-Inhibitor-Ziftomenib-in-Advanced-Gastrointestinal-Stromal-Tumors-GIST.html

    GLOBENEWSWIRE
    08 Aug 2024
    Share Share
    Kura Reports Preclinical Data on Menin Inhibitor's Potential in Diabetes
    Kura Reports Preclinical Data on Menin Inhibitor's Potential in Diabetes

    24 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/24/2902881/35186/en/Kura-Oncology-Reports-Preclinical-Data-Supporting-Potential-for-Menin-Inhibitor-in-Diabetes.html

    GLOBENEWSWIRE
    24 Jun 2024
    Share Share
    Kura Completes Ziftomenib NPM1-Mutant AML Trial Enrollment
    Kura Completes Ziftomenib NPM1-Mutant AML Trial Enrollment

    14 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/14/2881267/35186/en/Kura-Oncology-Completes-Enrollment-in-Registration-Directed-Trial-of-Ziftomenib-in-NPM1-Mutant-AML.html

    GLOBENEWSWIRE
    14 May 2024
    Share Share